Tesamorelin cycle length: what actually decides how long you run it

Someone posted on r/Peptides recently asking how to think about tesamorelin cycling alongside MOTS-c, and buried in the replies was the real question: is there an actual rule for tesamorelin cycle length, or is everyone just guessing at 8 weeks because that's what shows up on every cheat sheet. Short answer: the tesamorelin trials never cycled at all, they ran continuous daily dosing for up to a year, and the 5-days-on/2-days-off, 8-week-block pattern you see everywhere is a practitioner convention built around IGF-1 monitoring, not something pulled from the pivotal research.

That gap between what got tested and what people actually run is worth sitting with for a minute, because it changes how you should think about your own schedule.

What the trials actually did

The two Phase 3 trials that got tesamorelin approved as Egrifta dosed it once daily, continuously, for 26 weeks in the primary analysis, with people who continued into the extension phase running it for a full year. One trial pooled 806 patients and found visceral fat down about 15.4% at 26 weeks, holding around 17.5% through the full year in people who stayed on it, with no meaningful damage to glucose control (PMID 20554713). A second trial in 404 people found similar numbers, roughly 11% at six months climbing to 18% at twelve (PMID 20101189). A 2026 meta-analysis pooling five RCTs backed that pattern up again: visceral fat down, liver fat down, waist down, and lean mass actually up by about 1.4 kg (PMID 41545261).

None of that involved a scheduled break. The people who benefited most were the ones who stayed on it the longest. So if you're asking whether the trial data itself demands cycling, it doesn't. The trials answer a different question: does continuous dosing work? Yes, for as long as researchers followed people.

Why the community cycles anyway

The 5-on/2-off, 8-week-block pattern comes from practitioner convention, not from a study arm. The logic behind it is IGF-1 management. Tesamorelin works by getting your own pituitary to release more growth hormone in its natural pulsing rhythm, which is a smarter design than injecting raw GH with no brakes, since your body's own feedback loop is still intact. But sustained GH elevation still drives sustained IGF-1 elevation, and IGF-1 is a mitogen, meaning its job is to tell cells to grow and divide. That's exactly what you want in muscle tissue and exactly what you don't want feeding something that shouldn't be growing.

Practitioners who build in a break are managing that curve rather than responding to a documented cycling-related risk. The trials themselves didn't cycle and didn't show a cancer signal over their follow-up window, but those trials also only ran a year at most, and cancer can take far longer than that to show up. Building in periodic breaks and getting labs done is a reasonable hedge against a risk nobody has definitively measured either way.

Two of the peptide's better-studied secondary effects reinforce why people don't want to just run it forever without checking in. A 12-month RCT in fatty liver patients found reduced hepatic fat alongside slower fibrosis progression (PMID 32701508, PMID 33852720), and a 20-week RCT in older adults found improved executive function (PMID 22869065). Those are real, replicated benefits worth protecting, and the way you protect them long-term is by keeping IGF-1 in a sane range rather than chasing it as high as possible.

The protocol most people actually run

The trial dose is 2 mg once daily. The community version splits that into 1 mg in the morning and 1 mg at night, on a 5-days-on/2-days-off weekly rhythm, for an 8-week block, then a break before restarting. Total daily dose lands close to the trial number either way; the split is mostly about mirroring the natural GH pulse rather than chasing more total drug. Some people prefer a single evening dose closer to what the trials actually tested, since the biggest natural GH pulse fires in early deep sleep. I've seen both approaches work fine with clients, and the difference between them matters less than people think it does.

If you're running tesamorelin alongside MOTS-c, which was the actual question behind that Reddit thread, treat the two schedules independently. They work on different systems, MOTS-c on mitochondrial function and tesamorelin on the GH/IGF-1 axis, and there's no dedicated trial on running them together, so don't assume one cycle length applies to both. More on the mechanics of tesamorelin dosing and reconstitution is in the tesamorelin encyclopedia entry, and if you're weighing it against a similar GH-axis peptide, the CJC-1295 vs tesamorelin comparison walks through that trade-off.

Now the part my lawyer makes me say, and he's right: the doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice. Consult a qualified physician before beginning any protocol.

The practical version I'd give a friend: if you're brand new to it, run the 8-week block, get baseline and follow-up IGF-1 labs, and use the break to actually check where those numbers landed rather than skipping it out of habit. If your labs come back mid-range and nothing else is flagged, there's no rule that says you must stop at exactly eight weeks. If they're pushing the upper end of normal, that's your signal to extend the break, not shorten it. The cycle length question has less to do with a fixed calendar and more to do with what your own bloodwork is telling you.